Product Name: Voclosporin
Form: Free base
CAS No: 515814-01-4
Molar Mass: 1214.62
Chemical Formula: C63H111N11O12
Synonyms: ISAtx-247
Storage: Store at -20℃
Target: calcineurin (PP2B)
Application:
Voclosporin (CAS: 515814-01-4) is a synthetic calcineurin inhibitor derived from cyclosporine A, used in the treatment of various autoimmune diseases, particularly lupus nephritis and other forms of nephrotic syndrome. It functions by selectively binding to cyclophilin within T-lymphocytes, thereby inhibiting calcineurin activity and preventing the dephosphorylation of nuclear factor of activated T-cells (NFAT). This cascade ultimately leads to the suppression of T-cell activation and the production of pro-inflammatory cytokines. In pharmaceutical chemistry, voclosporin's targeted inhibition of calcineurin represents a significant advancement in the management of autoimmune kidney diseases, offering a more specific and potentially safer alternative to traditional immunosuppressive therapies like cyclosporine A. Its application underscores its importance in improving outcomes and quality of life for patients with lupus nephritis and other autoimmune kidney disorders. Additionally, ongoing research explores voclosporin's potential in other autoimmune and inflammatory conditions, highlighting its versatility in immunomodulatory therapeutics.
Current Research:
Voclosporin is a novel, oral selective inhibitor of calcineurin, primarily used in the treatment of lupus nephritis (LN), a severe kidney complication of systemic lupus erythematosus (SLE). SLE is an autoimmune disease that leads to widespread inflammation and tissue damage, and lupus nephritis can result in kidney failure if not managed effectively. Voclosporin specifically targets the calcineurin pathway, which plays a key role in immune cell activation and the progression of inflammatory processes. By inhibiting calcineurin, Voclosporin helps to reduce kidney inflammation, preserve renal function, and improve outcomes for patients with lupus nephritis.
Mechanism of Action
Voclosporin works by inhibiting calcineurin, a calcium and calmodulin-dependent serine/threonine phosphatase that is involved in the activation of T cells and other immune responses. Calcineurin’s activation is essential for the transcription of interleukin-2 (IL-2) and other pro-inflammatory cytokines, which contribute to the immune-mediated inflammation seen in diseases like lupus nephritis. By selectively binding to calcineurin and blocking its activity, Voclosporin prevents T-cell activation and the subsequent release of inflammatory mediators. Unlike traditional calcineurin inhibitors, such as cyclosporine, Voclosporin is more selective, providing an improved side-effect profile and better pharmacokinetics, including fewer drug-drug interactions.
Indications and Uses
Voclosporin is primarily indicated for the treatment of lupus nephritis (LN) in adults. Lupus nephritis is a life-threatening complication of systemic lupus erythematosus (SLE) that results in inflammation of the kidneys and, if untreated, can lead to end-stage renal disease. Voclosporin is typically used in combination with other immunosuppressive therapies such as mycophenolate mofetil (MMF) and corticosteroids to achieve disease remission. The drug helps to manage proteinuria, reduce kidney inflammation, and protect against renal damage. Voclosporin is administered orally, with dosing adjusted based on renal function and other clinical factors.
Efficacy and Clinical Benefits
Voclosporin has demonstrated significant efficacy in clinical trials for the treatment of lupus nephritis. In the pivotal AURORA trial, Voclosporin in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids showed substantial improvements in renal response, with higher rates of complete renal remission and reduced proteinuria compared to the standard treatment regimen. The combination therapy also led to better preservation of renal function, which is critical in preventing long-term kidney damage in patients with lupus nephritis. Furthermore, Voclosporin has been shown to be effective in patients who are refractory to other treatments, making it an important option for patients who have not responded adequately to conventional immunosuppressive therapies.
Safety and Tolerability
Voclosporin is generally well tolerated, although it can cause side effects, particularly related to its immunosuppressive activity. The most common adverse effects include hypertension, headache, nausea, and diarrhea. Because Voclosporin suppresses immune function, there is an increased risk of infections, including respiratory and urinary tract infections. Monitoring of renal function, blood pressure, and drug levels is recommended during therapy to optimize dosing and minimize the risk of adverse effects. Additionally, there is a known risk of nephrotoxicity, particularly in patients with pre-existing renal impairment, so dose adjustments may be necessary for these individuals. Regular monitoring of renal parameters and blood pressure is essential during treatment to avoid complications.
Advantages and Limitations
One of the main advantages of Voclosporin is its selective inhibition of calcineurin, which provides a more targeted approach with a reduced risk of side effects compared to older calcineurin inhibitors like cyclosporine and tacrolimus. This selectivity translates into fewer drug-drug interactions and a potentially improved safety profile, particularly regarding nephrotoxicity. Voclosporin’s oral administration makes it a convenient option for patients compared to intravenous therapies, offering an easier treatment regimen for long-term use. However, its use is limited by its potential side effects, particularly hypertension and infection risks, which require regular monitoring. Additionally, while it is effective in treating lupus nephritis, Voclosporin does not address all aspects of SLE and may need to be used in combination with other agents to manage the full spectrum of the disease.
Future Directions
Ongoing research is exploring the potential of Voclosporin in other autoimmune conditions and inflammatory disorders, where T-cell mediated immune activation plays a significant role. Future studies may investigate its efficacy in combination with newer biologic therapies or other immunosuppressive agents to provide more comprehensive treatment for patients with complex autoimmune diseases. Furthermore, there is interest in assessing the long-term safety and renal outcomes of Voclosporin in patients with lupus nephritis, as long-term data will help refine its role in managing this chronic and often debilitating disease. Advances in personalized medicine may also enable more precise dosing and treatment regimens, maximizing the benefit of Voclosporin for each individual patient.
Reference:
Heo, Y. A. (2021). Voclosporin: first approval. Drugs, 81, 605-610.
Get a Quote
LinkPeptide
